K
Koichi Ando
Researcher at Showa University
Publications - 38
Citations - 452
Koichi Ando is an academic researcher from Showa University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 6, co-authored 27 publications receiving 218 citations. Previous affiliations of Koichi Ando include Vanderbilt University.
Papers
More filters
Journal ArticleDOI
Receptor Tyrosine Kinase-Targeted Cancer Therapy.
TL;DR: Representation of RTKs important for developing cancer therapeutics and predicting or evaluated resistance mechanisms are described in this review.
Journal ArticleDOI
Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.
Toshimitsu Yamaoka,Tohru Ohmori,Motoi Ohba,Satoru Arata,Yasunori Murata,Sojiro Kusumoto,Koichi Ando,Hiroo Ishida,Tsukasa Ohnishi,Yasutsuna Sasaki +9 more
TL;DR: Heterogeneous mechanisms of acquired resistance were identified following long-term exposure to increasing doses of afatinib in EGFR-mutant lung adenocarcinoma PC-9 cells and constitute the first report showing acquired wild-type KRAS overexpression and attenuation ofafatinib resistance following a drug holiday.
Journal ArticleDOI
Enhancement of Sensitivity to Tumor Necrosis Factor α in Non–Small Cell Lung Cancer Cells with Acquired Resistance to Gefitinib
Koichi Ando,Tohru Ohmori,Fumiko Inoue,Tsuyoki Kadofuku,Takamichi Hosaka,Hiroo Ishida,Takao Shirai,Kentaro Okuda,Takashi Hirose,Naoya Horichi,Kazuto Nishio,Nagahiro Saijo,Mitsuru Adachi,Toshio Kuroki +13 more
TL;DR: It is suggested that therapy with TNF-α would be effective in some cases of non-small-cell lung cancer that have acquired resistance to gefitinib.
Journal ArticleDOI
Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury.
Tohru Ohmori,Toshimitsu Yamaoka,Koichi Ando,Sojiro Kusumoto,Yasunari Kishino,Ryou Manabe,Hironori Sagara +6 more
TL;DR: In this paper, the authors evaluated the relationship between EGFR-TKIs and interstitial lung disease (ILD), especially lung fibrosis, chronic obstructive pulmonary disease, and poor performance status.
Journal ArticleDOI
Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis
Koichi Ando,Kaho Akimoto,Hiroki Sato,Ryo Manabe,Yasunari Kishino,Tetsuya Homma,Sojiro Kusumoto,Toshimitsu Yamaoka,Akihiko Tanaka,Tohru Ohmori,Hironori Sagara +10 more
TL;DR: This study provides critical information to clinicians regarding the efficacy of brigatinib for ALK-p, AlK-inhibitor-naïve, advanced NSCLC patients, with and without CNS metastasis, using a Bayesian model with non-informative prior distribution and assessed the between-study heterogeneity of the studies.